Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Molecular Diagnosis & Therapy
Erschienen in: Molecular Diagnosis & Therapy 4/2016

01.08.2016 | Review Article

Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases

verfasst von: Amir Abbas Momtazi, Giuseppe Derosa, Pamela Maffioli, Maciej Banach, Amirhossein Sahebkar

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Curcumin is a bioactive polyphenol occurring in the rhizomes of Curcuma longa. It is well-reputed for its chemopreventive and anticancer properties; however, recent evidence has revealed numerous biological and pharmacological effects of curcumin that are relevant to the treatment of non-cancer diseases. Mechanistically, curcumin exerts its pharmacological effects through anti-inflammatory and antioxidant mechanisms via interaction with different signaling molecules and transcription factors. In addition, epigenetic modulators such as microRNAs (miRs) have emerged as novel targets of curcumin. Curcumin was found to modulate the expression of several pathogenic miRs in brain, ocular, renal, and liver diseases. The present systematic review was conducted to identify miRs that are regulated by curcumin in non-cancer diseases.
Literatur
1.
Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal. 2008;10(3):511–46.PubMedCrossRef
2.
Akram M, Shahab-Uddin AA, Usmanghani K, Hannan A, Mohiuddin E, Asif M. Curcuma longa and curcumin: a review article. Rom J Biol Plant Biol. 2010;55:65–70.
3.
Clinical development plan. curcumin. J Cell Biochem Suppl. 1996;26:72–85.
4.
Mahady G, Pendland S, Yun G, Lu Z. Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen. Anticancer Res. 2001;22(6C):4179–81.
5.
Kuttan R, Bhanumathy P, Nirmala K, George M. Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett. 1985;29(2):197–202.PubMedCrossRef
6.
7.
Iranshahi M, Sahebkar A, Hosseini S, Takasaki M, Konoshima T, Tokuda H. Cancer chemopreventive activity of diversin from Ferula diversivittata in vitro and in vivo. Phytomedicine. 2010;17(3):269–73.PubMedCrossRef
8.
Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev. 2010;29(3):405–34.PubMedPubMedCentralCrossRef
9.
Esmaily H, Sahebkar A, Iranshahi M, Ganjali S, Mohammadi A, Ferns G, et al. An investigation of the effects of curcumin on anxiety and depression in obese individuals: a randomized controlled trial. Chin J Integr Med. 2015;21(5):332–8.PubMedCrossRef
10.
Chen FY, Zhou J, Guo N, Ma WG, Huang X, Wang H, Yuan ZY. Curcumin retunes cholesterol transport homeostasis and inflammation response in M1 macrophage to prevent atherosclerosis. Biochem Biophys Res Commun. 2015;467(4):872–8. PubMedCrossRef
11.
Sahebkar A, Mohammadi A, Atabati A, Rahiman S, Tavallaie S, Iranshahi M, et al. Curcuminoids modulate pro-oxidant–antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res. 2013;27(12):1883–8.PubMedCrossRef
12.
Panahi Y, Alishiri GH, Parvin S, Sahebkar A. Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: results of a randomized controlled trial. J Diet Suppl. 2016;13(2):209–20.PubMedCrossRef
13.
Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A. Curcuminoid Treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res. 2014;28(11):1625–31.PubMedCrossRef
14.
Ganjali S, Sahebkar A, Mahdipour E, Jamialahmadi K, Torabi S, Akhlaghi S, et al. Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. SciWorldJ. 2014;2014:898361.
15.
Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res. 2014;28(10):1461–7.PubMedCrossRef
16.
Panahi Y, Sahebkar A, Parvin S, Saadat A. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem. 2012;49(6):580–8.PubMedCrossRef
17.
Panahi Y, Ghanei M, Bashiri S, Hajihashemi A, Sahebkar A. Short-term curcuminoid supplementation for chronic pulmonary complications due to sulfur mustard intoxication: positive results of a randomized double-blind placebo-controlled trial. Drug Res. 2015;65(11):567–73.
18.
Mohammadi A, Sahebkar A, Iranshahi M, Amini M, Khojasteh R, Ghayour-Mobarhan M, et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res. 2013;27(3):374–9.PubMedCrossRef
19.
Um MY, Hwang KH, Choi WH, Ahn J, Jung CH, Ha TY. Curcumin attenuates adhesion molecules and matrix metalloproteinase expression in hypercholesterolemic rabbits. Nutr Res. 2014;34(10):886–93.PubMedCrossRef
20.
Yang YS, Su YF, Yang HW, Lee YH, Chou JI, Ueng KC. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res. 2014;28(12):1770–7.PubMedCrossRef
21.
Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res. 2014;28(5):633–42.PubMedCrossRef
22.
Fan C, Wo X, Qian Y, Yin J, Gao L. Effect of curcumin on the expression of LDL receptor in mouse macrophages. J Ethnopharmacol. 2006;105(1–2):251–4.PubMedCrossRef
23.
Arafa HM. Curcumin attenuates diet-induced hypercholesterolemia in rats. Med Sci Mon. 2005;11(7):BR228–34.
24.
Asai A, Miyazawa T. Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. J Nutr. 2001;131(11):2932–5.PubMed
25.
Sahebkar A. Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol. 2014;11(2):123.PubMedCrossRef
26.
Sahebkar A. Low-density lipoprotein is a potential target for curcumin: novel mechanistic insights. Basic Clin Pharmacol Toxicol. 2014;114(6):437–8.PubMedCrossRef
27.
Seyedzadeh MH, Safari Z, Zare A, Gholizadeh Navashenaq J, Razavi SA, Kardar GA, et al. Study of curcumin immunomodulatory effects on reactive astrocyte cell function. Int Immunopharmacol. 2014;22(1):230–5.PubMedCrossRef
28.
Sankar P, Telang AG, Suresh S, Kesavan M, Kannan K, Kalaivanan R, et al. Immunomodulatory effects of nanocurcumin in arsenic-exposed rats. Int Immunopharmacol. 2013;17(1):65–70.PubMedCrossRef
29.
Sahebkar A, Cicero AF, Simental-Mendia LE, Aggarwal BB, Gupta SC. Curcumin downregulates human tumor necrosis factor-alpha levels: a systematic review and meta-analysis ofrandomized controlled trials. Pharmacol Res. 2016;107:234–42.PubMedCrossRef
30.
Sharma O. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol. 1976;25(15):1811–2.PubMedCrossRef
31.
Panahi Y, Sahebkar A, Amiri M, Davoudi SM, Beiraghdar F, Hoseininejad SL, et al. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br J Nutr. 2012;108(7):1272–9.PubMedCrossRef
32.
Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors. 2013;39(2):197–208.PubMedCrossRef
33.
Shen LL, Jiang ML, Liu SS, Cai MC, Hong ZQ, Lin LQ, et al. Curcumin improves synaptic plasticity impairment induced by HIV-1gp120 V3 loop. Neural Regen Res. 2015;10(6):925–31.PubMedPubMedCentralCrossRef
34.
Chen K, An Y, Tie L, Pan Y, Li X. Curcumin protects neurons from glutamate-induced excitotoxicity by membrane anchored AKAP79-PKA interaction network. Evid Based Complement Alternat Med. 2015;2015:706207.PubMedPubMedCentral
35.
Wang BF, Cui ZW, Zhong ZH, Sun YH, Sun QF, Yang GY, et al. Curcumin attenuates brain edema in mice with intracerebral hemorrhage through inhibition of AQP4 and AQP9 expression. Acta Pharmacol Sin. 2015;36(8):939–48.PubMedPubMedCentralCrossRef
36.
Yang Y, Wu X, Wei Z, Dou Y, Zhao D, Wang T, et al. Oral curcumin has anti-arthritic efficacy through somatostatin generation via cAMP/PKA and Ca(2 +)/CaMKII signaling pathways in the small intestine. Pharmacol Res. 2015;95–96:71–81.PubMedCrossRef
37.
Kuncha M, Naidu VG, Sahu BD, Gadepalli SG, Sistla R. Curcumin potentiates the anti-arthritic effect of prednisolone in Freund’s complete adjuvant-induced arthritic rats. J Pharm Pharmacol. 2014;66(1):133–44.PubMedCrossRef
38.
Kumar K, Rai AK. Proniosomal formulation of curcumin having anti-inflammatory and anti-arthritic activity in different experimental animal models. Die Pharmazie. 2012;67(10):852–7.PubMed
39.
Panahi Y, Badeli R, Karami GR, Sahebkar A. Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother Res. 2015;29(1):17–21.PubMedCrossRef
40.
Sahebkar A, Henrotin Y. Analgesic efficacy and safety of curcuminoids in clinical practice: a systematic review and meta-analysis of randomized controlled trials. Pain Med. 2015. doi:10.​1093/​pm/​pnv024 PubMed
41.
Sharma S, Kulkarni SK, Chopra K. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol. 2006;33(10):940–5.PubMedCrossRef
42.
Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, et al. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem. 2005;53(4):959–63.PubMedCrossRef
43.
Sahebkar A. Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril. 2010;94(5):e75–6 (author reply e7).
44.
Hasan ST, Zingg JM, Kwan P, Noble T, Smith D, Meydani M. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice. Atherosclerosis. 2014;232(1):40–51.PubMedCrossRef
45.
Sidhu GS, Singh AK, Thaloor D, Banaudha KK, Patnaik GK, Srimal RC, et al. Enhancement of wound healing by curcumin in animals. Wound Repair Regen. 1998;6(2):167–77.PubMedCrossRef
46.
Negi P, Jayaprakasha G, Jagan Mohan Rao L, Sakariah K. Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture. J Agric Food Chem. 1999;47(10):4297–300.
47.
48.
Kim M-K, Choi G-J, Lee H-S. Fungicidal property of Curcuma longa L. rhizome-derived curcumin against phytopathogenic fungi in a greenhouse. J Agric Food Chem. 2003;51(6):1578–81.PubMedCrossRef
49.
Reddy RC, Vatsala PG, Keshamouni VG, Padmanaban G, Rangarajan PN. Curcumin for malaria therapy. Biochem Biophys Res Comm. 2005;326(2):472–4.PubMedCrossRef
50.
Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev. 2009;14(3):277.
51.
Teiten MH, Dicato M, Diederich M. Curcumin as a regulator of epigenetic events. Mol Nutr Food Res. 2013;57(9):1619–29.PubMedCrossRef
52.
Li Y, Kong D, Wang Z, Sarkar FH. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res. 2010;27(6):1027–41.PubMedPubMedCentralCrossRef
53.
Sawan C, Vaissière T, Murr R, Herceg Z. Epigenetic drivers and genetic passengers on the road to cancer. Mutat Res. 2008;642(1):1–13.PubMedCrossRef
54.
55.
Hutvágner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science. 2002;297(5589):2056–60.PubMedCrossRef
56.
Williams RJ, Spencer JP. Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. Free Radic Biol Med. 2012;52(1):35–45.PubMedCrossRef
57.
Ng R, Song G, Roll GR, Frandsen NM, Willenbring H. A microRNA-21 surge facilitates rapid cyclin D1 translation and cell cycle progression in mouse liver regeneration. J Clin Invest. 2012;122(3):1097.PubMedPubMedCentralCrossRef
58.
Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478(7369):404–7.PubMedPubMedCentralCrossRef
59.
Zhang P, Bill K, Liu J, Young E, Peng T, Bolshakov S, et al. MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling. Cancer Res. 2012;72(7):1751–62.PubMedPubMedCentralCrossRef
60.
Taganov KD, Boldin MP, Chang K-J, Baltimore D. NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci. 2006;103(33):12481–6.PubMedPubMedCentralCrossRef
61.
Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature. 2012;481(7380):190–4.CrossRef
62.
Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769–73.PubMedCrossRef
63.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–8.PubMedCrossRef
64.
Li Y, Kowdley KV. MicroRNAs in common human diseases. Genom Proteom Bioinform. 2012;10(5):246–53.CrossRef
65.
Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev. 2011;91(3):827–87.PubMedCrossRef
66.
67.
68.
69.
Zheng J, Wu C, Lin Z, Guo Y, Shi L, Dong P, et al. Curcumin up-regulates phosphatase and tensin homologue deleted on chromosome 10 through microRNA-mediated control of DNA methylation–a novel mechanism suppressing liver fibrosis. FEBS J. 2014;281(1):88–103.PubMedCrossRef
70.
Hassan ZK, Al-Olayan EM. Curcumin reorganizes miRNA expression in a mouse model of liver fibrosis. Asian Pac J Cancer Prev. 2012;13:5405–8.PubMedCrossRef
71.
Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem. 2005;74:481–514.PubMedCrossRef
72.
Yang N, Mahato RI. GFAP promoter-driven RNA interference on TGF-β1 to treat liver fibrosis. Pharm Res. 2011;28(4):752–61.PubMedCrossRef
73.
Kulkarni SK, Bhutani MK, Bishnoi M. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology (Berl). 2008;201(3):435–42.PubMedCrossRef
74.
Wang R, Li Y-B, Li Y-H, Xu Y, Wu H-L, Li X-J. Curcumin protects against glutamate excitotoxicity in rat cerebral cortical neurons by increasing brain-derived neurotrophic factor level and activating TrkB. Brain Res. 2008;1210:84–91.
75.
Bhutani MK, Bishnoi M, Kulkarni SK. Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes. Pharmacol Biochem Behav. 2009;92(1):39–43.PubMedCrossRef
76.
Li Y-C, Wang F-M, Pan Y, Qiang L-Q, Cheng G, Zhang W-Y, et al. Antidepressant-like effects of curcumin on serotonergic receptor-coupled AC-cAMP pathway in chronic unpredictable mild stress of rats. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(3):435–49.PubMedCrossRef
77.
Bishnoi M, Chopra K, Kulkarni SK. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. Pharmacol Biochem Behav. 2008;88(4):511–22.PubMedCrossRef
78.
Sharma S, Chopra K, Kulkarni SK. Effect of insulin and its combination with resveratrol or curcumin in attenuation of diabetic neuropathic pain: participation of nitric oxide and TNF-alpha. Phytother Res. 2007;21(3):278–83.PubMedCrossRef
79.
Kulkarni S, Dhir A, Akula KK. Potentials of curcumin as an antidepressant. SciWorldJ. 2009;9:1233–41.
80.
Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280(7):5892–901.PubMedCrossRef
81.
Patil SP, Tran N, Geekiyanage H, Liu L, Chan C. Curcumin-induced upregulation of the anti-tau cochaperone BAG2 in primary rat cortical neurons. Neurosci Lett. 2013;554:121–5.PubMedCrossRef
82.
Shakeri A, Sahebkar A. Optimized curcumin formulations for the treatment of Alzheimer’s disease: a patent evaluation. J Neurosci Res. 2016;94(2):111–3.PubMedCrossRef
83.
Sahebkar A. Autophagic activation: a key piece of the puzzle for the curcumin-associated cognitive enhancement? J Psychopharmacol. 2016;30(1):93–4.PubMedCrossRef
84.
85.
Lee M-S, Kwon YT, Li M, Peng J, Friedlander RM, Tsai L-H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 2000;405(6784):360–4.PubMedCrossRef
86.
Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 1992;42(3):631–9.PubMedCrossRef
87.
Barrachina M, Maes T, Buesa C, Ferrer I. Lysosome-associated membrane protein 1 (LAMP-1) in Alzheimer’s disease. Neuropathol Appl Neurobiol. 2006;32(5):505–16.PubMedCrossRef
88.
Carrettiero DC, Hernandez I, Neveu P, Papagiannakopoulos T, Kosik KS. The cochaperone BAG2 sweeps paired helical filament-insoluble tau from the microtubule. J Neurosci. 2009;29(7):2151–61.PubMedPubMedCentralCrossRef
89.
Sethi P, Lukiw WJ. Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer’s disease temporal lobe neocortex. Neuroscience Lett. 2009;459(2):100–4.CrossRef
90.
Lukiw WJ, Zhao Y, Cui JG. An NF-κB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem. 2008;283(46):31315–22.PubMedPubMedCentralCrossRef
91.
Lukiw WJ, Pogue AI. Induction of specific micro RNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells. J Inorg Biochem. 2007;101(9):1265–9.PubMedPubMedCentralCrossRef
92.
Cui JG, Li YY, Zhao Y, Bhattacharjee S, Lukiw WJ. Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-κB in stressed human astroglial cells and in Alzheimer disease. J Biol Chem. 2010;285(50):38951–60.PubMedPubMedCentralCrossRef
93.
Pogue AI, Percy ME, Cui J-G, Li YY, Bhattacharjee S, Hill JM, et al. Up-regulation of NF-kB-sensitive miRNA-125b and miRNA-146a in metal sulfate-stressed human astroglial (HAG) primary cell cultures. J Inorg Biochem. 2011;105(11):1434–7.PubMedPubMedCentralCrossRef
94.
Li Y, Cui J, Hill J, Bhattacharjee S, Zhao Y, Lukiw W. Increased expression of miRNA-146a in Alzheimer’s disease transgenic mouse models. Neurosci Lett. 2011;487(1):94–8.PubMedCrossRef
95.
Angel-Morales G, Noratto G, Mertens-Talcott SU. Standardized curcuminoid extract (Curcuma longa l.) decreases gene expression related to inflammation and interacts with associated microRNAs in human umbilical vein endothelial cells (HUVEC). Food Funct. 2012;3(12):1286–93.
96.
Zaky A, Mahmoud M, Awad D, El Sabaa BM, Kandeel KM, Bassiouny AR. Valproic acid potentiates curcumin-mediated neuroprotection in lipopolysaccharide induced rats. Front Cell Neurosci. 2014;8:337.PubMedPubMedCentralCrossRef
97.
Howell JC, Chun E, Farrell AN, Hur EY, Caroti CM, Iuvone PM, et al. Global microRNA expression profiling: curcumin (diferuloylmethane) alters oxidative stress-responsive microRNAs in human ARPE-19 cells. Mol Vis. 2013;19:544.PubMedPubMedCentral
98.
Lukiw WJ, Surjyadipta B, Dua P, Alexandrov PN. Common micro RNAs (miRNAs) target complement factor H (CFH) regulation in Alzheimer’s disease (AD) and in age-related macular degeneration (AMD). Int J Biochem Mol Biol. 2012;3(1):105–16.PubMedPubMedCentral
99.
Hill JM, Dua P, Clement C, Lukiw WJ. An evaluation of progressive amyloidogenic and pro-inflammatory change in the primary visual cortex and retina in Alzheimer’s disease (AD). Front Neurosci. 2014;8:347.PubMedPubMedCentralCrossRef
100.
Hu S, Maiti P, Ma Q, Zuo X, Jones MR, Cole GM, et al. Clinical development of curcumin in neurodegenerative disease. Expert Rev Neurother. 2015;15(6):629–37.PubMedCrossRef
101.
Wang LL, Sun Y, Huang K, Zheng L. Curcumin, a potential therapeutic candidate for retinal diseases. Mol Nutr Food Res. 2013;57(9):1557–68.PubMedCrossRef
102.
Gross JL, De Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164–76.PubMedCrossRef
103.
Giunti S, Barit D, Cooper ME. Mechanisms of diabetic nephropathy role of hypertension. Hypertension. 2006;48(4):519–26.PubMedCrossRef
104.
Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med. 1982;72(3):375–80.PubMedCrossRef
105.
Dessapt C, Baradez MO, Hayward A, Dei Cas A, Thomas SM, Viberti G, et al. Mechanical forces and TGFβ1 reduce podocyte adhesion through α3β1 integrin downregulation. Nephrol Dial Transplant. 2009;24(9):2645–55.PubMedCrossRef
106.
Kriz W, Shirato I, Nagata M, LeHir M, Lemley KV. The podocyte’s response to stress: the enigma of foot process effacement. Am J Physiol Renal Physiol. 2013;304(4):F333–47.PubMedCrossRef
107.
Hartner A, Cordasic N, Menendez-Castro C, Volkert G, Yabu JM, Kupraszewicz-Hutzler M, et al. Lack of α8-integrin aggravates podocyte injury in experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2010;299(5):F1151–7.PubMedCrossRef
108.
109.
Li D, Lu Z, Jia J, Zheng Z, Lin S. Changes in microRNAs associated with podocytic adhesion damage under mechanical stress. J Renin Angiotensin Aldosterone Syst. 2013;14(2):97–102.PubMedCrossRef
110.
Li D, Lu Z, Jia J, Zheng Z, Lin S. miR-124 is related to podocytic adhesive capacity damage in STZ-induced uninephrectomized diabetic rats. Kidney Blood Press Res. 2013;37(4–5):422–31.PubMedCrossRef
111.
Moini Zanjani T, Ameli H, Labibi F, Sedaghat K, Sabetkasaei M. The attenuation of pain behavior and serum COX-2 concentration by curcumin in a rat model of neuropathic pain. Korean J Pain. 2014;27(3):246–52.
112.
Wei C, Möller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med. 2008;14(1):55–63.PubMedCrossRef
113.
Palanisamy N, Kannappan S, Anuradha CV. Genistein modulates NF-κB-associated renal inflammation, fibrosis and podocyte abnormalities in fructose-fed rats. Eur J Pharmacol. 2011;667(1):355–64.PubMedCrossRef
114.
Wang W, Ding X-Q, Gu T-T, Song L, Li J-M, Xue Q-C, et al. Pterostilbene and allopurinol reduce fructose-induced podocyte oxidative stress and inflammation via microRNA-377. Free Radicl Biol Med. 2015;83:214–26.CrossRef
115.
Harvey SJ, Jarad G, Cunningham J, Goldberg S, Schermer B, Harfe BD, et al. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol. 2008;19(11):2150–8.PubMedPubMedCentralCrossRef
116.
Zhdanova O, Srivastava S, Di L, Li Z, Tchelebi L, Dworkin S, et al. The inducible deletion of Drosha and microRNAs in mature podocytes results in a collapsing glomerulopathy. Kidney Int. 2011;80(7):719–30.PubMedPubMedCentralCrossRef
117.
Ho J, Ng KH, Rosen S, Dostal A, Gregory RI, Kreidberg JA. Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J Am Soc Nephrol. 2008;19(11):2069–75.PubMedPubMedCentralCrossRef
118.
Shi S, Yu L, Chiu C, Sun Y, Chen J, Khitrov G, et al. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol. 2008;19(11):2159–69.PubMedPubMedCentralCrossRef
119.
Ding XQ, Gu TT, Wang W, Song L, Chen TY, Xue QC, et al. Curcumin protects against fructose-induced podocyte insulin signaling impairment through upregulation of miR-206. Mol Nutr Food Res. 2015;59(12):2355–70.PubMedCrossRef
120.
Huang GS, Yang S-M, Hong M-Y, Yang P-C, Liu Y-C. Differential gene expression of livers from ApoE deficient mice. Life Sci. 2000;68(1):19–28.PubMedCrossRef
121.
Milenkovic D, Deval C, Gouranton E, Landrier J-F, Scalbert A, Morand C, et al. Modulation of miRNA expression by dietary polyphenols in apoE deficient mice: a new mechanism of the action of polyphenols. PLoS One. 2012;7(1):e29837.PubMedPubMedCentralCrossRef
122.
Li D, Lu Z, Jia J, Zheng Z, Lin S. Curcumin ameliorates podocytic adhesive capacity damage under mechanical stress by inhibiting miR-124 expression. Kidney Blood Press Res. 2013;38(1):61–71.PubMedCrossRef
Metadaten
Titel
Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases
verfasst von
Amir Abbas Momtazi
Giuseppe Derosa
Pamela Maffioli
Maciej Banach
Amirhossein Sahebkar
Publikationsdatum
01.08.2016
Verlag
Springer International Publishing
Erschienen in
Molecular Diagnosis & Therapy / Ausgabe 4/2016
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-016-0202-7

Weitere Artikel der Ausgabe 4/2016

Molecular Diagnosis & Therapy 4/2016 Zur Ausgabe

Current Opinion

The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment

Original Research Article

Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer

Review Article

Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy

Original Research Article

Prognostic Significance of Early Tumor Shrinkage Under Second-Line Targeted Therapy for Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Study in Japan

Original Research Article

Detecting Primary KIT Mutations in Presurgical Plasma of Patients with Gastrointestinal Stromal Tumor

Original Research Article

A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise